MX2024013669A - Novedosas proteinas de fusion cd200 - Google Patents

Novedosas proteinas de fusion cd200

Info

Publication number
MX2024013669A
MX2024013669A MX2024013669A MX2024013669A MX2024013669A MX 2024013669 A MX2024013669 A MX 2024013669A MX 2024013669 A MX2024013669 A MX 2024013669A MX 2024013669 A MX2024013669 A MX 2024013669A MX 2024013669 A MX2024013669 A MX 2024013669A
Authority
MX
Mexico
Prior art keywords
fusion proteins
novel
mutations
relates
igg4
Prior art date
Application number
MX2024013669A
Other languages
English (en)
Spanish (es)
Inventor
Rebecca Ashfield
Original Assignee
Ducentis Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ducentis Biotherapeutics Ltd filed Critical Ducentis Biotherapeutics Ltd
Publication of MX2024013669A publication Critical patent/MX2024013669A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024013669A 2022-05-06 2024-11-05 Novedosas proteinas de fusion cd200 MX2024013669A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB202206673 2022-05-06
PCT/IB2023/054722 WO2023214388A1 (en) 2022-05-06 2023-05-05 Novel cd200 fusion proteins

Publications (1)

Publication Number Publication Date
MX2024013669A true MX2024013669A (es) 2025-02-10

Family

ID=86609511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013669A MX2024013669A (es) 2022-05-06 2024-11-05 Novedosas proteinas de fusion cd200

Country Status (10)

Country Link
US (1) US20260116946A1 (cg-RX-API-DMAC10.html)
EP (1) EP4519298A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025515191A (cg-RX-API-DMAC10.html)
KR (1) KR20250025619A (cg-RX-API-DMAC10.html)
CN (1) CN119522234A (cg-RX-API-DMAC10.html)
AU (1) AU2023265174A1 (cg-RX-API-DMAC10.html)
CA (1) CA3251039A1 (cg-RX-API-DMAC10.html)
IL (1) IL316697A (cg-RX-API-DMAC10.html)
MX (1) MX2024013669A (cg-RX-API-DMAC10.html)
WO (1) WO2023214388A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
WO2025106841A1 (en) * 2023-11-15 2025-05-22 The University Of Chicago Methods and compositions for inducing antigen specific tolerance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
EP1171154A2 (en) 1999-04-13 2002-01-16 Schering Corporation Uses of mammalian ox2 protein and related reagents
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2008089022A2 (en) 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Also Published As

Publication number Publication date
WO2023214388A1 (en) 2023-11-09
KR20250025619A (ko) 2025-02-24
CA3251039A1 (en) 2023-11-09
JP2025515191A (ja) 2025-05-13
US20260116946A1 (en) 2026-04-30
AU2023265174A1 (en) 2024-12-12
EP4519298A1 (en) 2025-03-12
CN119522234A (zh) 2025-02-25
IL316697A (en) 2024-12-01

Similar Documents

Publication Publication Date Title
US20250223315A1 (en) Protein purification with protein l
US12351622B2 (en) Modified product of Fc domain of antibody
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
RU2016139006A (ru) Мультимерные fc-белки
KR20250152665A (ko) Fc-함유 폴리펩타이드의 안정화
US11820809B2 (en) Multispecific antibodies facilitating selective light chain pairing
RS55609B1 (sr) Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
CN106459191B (zh) 选择具有修饰的FcRn相互作用的抗体的方法
MX2025002112A (es) Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
JP2019500850A5 (cg-RX-API-DMAC10.html)
MX386295B (es) Mutante cd200 y sus usos
JP2019511457A5 (cg-RX-API-DMAC10.html)
JP2022525661A5 (cg-RX-API-DMAC10.html)
US20230103563A1 (en) Split ch2 domains
BR112021000383A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a pd-l1
CN105793285A (zh) 多亚基结构的亚基的结合结构域用于将药物活性实体靶向递送至多亚基结构的用途
JP2024501770A5 (cg-RX-API-DMAC10.html)
MX2025013204A (es) Proteinas de fusion cd200
JP2019172702A (ja) 目的とする含量で不純物を含むTNFR−Fc融合タンパク質の製造方法
US20230357341A1 (en) Fusion protein containing erythropoietin polypeptide
AU2015202560B2 (en) Method for Making Antibody Fc-Heterodimeric Molecules Using Electrostatic Steering Effects
RU2025105731A (ru) Мутанты антител свиных
RU2025102187A (ru) Мутанты бычьих антител
RU2024103715A (ru) Рекомбинантные варианты белков r-спондинов и их применение
HK1233657A1 (en) Method for selecting antibodies with modified fcrn interaction